Dova Pharmaceuticals, Inc. (DOVA)
Dova Pharmaceuticals Enters Overbought Territory: Is A Drop Coming?
Dova Pharmaceuticals has moved higher as of late, but there could definitely be trouble on the horizon for this company.
Dova Pharmaceuticals rallies on buyout offer from Swedish Orphan Biovitrum
Dova Pharmaceuticals shares climbed 37% to $27.75 a share in premarket trade after Swedish Orphan Biovitrum said it will buy the company for $27.50 a share…
Dova Pharmaceuticals (DOVA) Jumps: Stock Rises 8.8%
Dova Pharmaceuticals (DOVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Dova Pharmaceuticals (DOVA) Reports Q2 Loss, Lags Revenue Estimates
Dova Pharmaceuticals (DOVA) delivered earnings and revenue surprises of -5.26% and -37.55%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Dova Pharmaceuticals (DOVA) in Focus: Stock Moves 9.1% Higher
Dova Pharmaceuticals (DOVA) shares rose more than 9% in the last trading session, amid huge volumes.
What's Driving The Rally At Small-Cap Biotech Dova?
Shares of thinly traded small-cap biotech Dova Pharmaceuticals Inc (NASDAQ: DOVA ) were solidly higher Thursday, adding to the gains they notched early in the week . Dova announced Tuesday that its Doptelet was granted marketing authorization in Europe for treating severe thrombocytopenia in adult patients with chronic liver disease. What Happened Dova, a pharma company focused on developing therapies for diseases with a high unmet need, said Thursday ahead … Full story available on Benzinga.com
Dova Receives Approval for Doptelet in Europe, Stock Up
Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.
Implied Volatility Surging for Dova Pharmaceuticals (DOVA) Stock Options
Investors need to pay close attention to Dova Pharmaceuticals (DOVA) stock based on the movements in the options market lately.
Dova Pharmaceuticals, Inc. (DOVA) Q1 2019 Earnings Call Transcript
DOVA earnings call for the period ending March 31, 2019.
Dova Pharmaceuticals' (DOVA) CEO David Zaccardelli on Q1 2019 Results - Earnings Call Transcript
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) Q1 2019 Earnings Conference Call May 7, 2019 9:00 AM ET Company Participants David Zaccardelli – President and Chief Ex
Dova Pharmaceuticals (DOVA) is down today: does this make sense?
Dova Pharmaceuticals (DOVA) today announced the FDA has completed their Priority Review and approved DOPTELET for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD), but the stock is down 11% in mid-day trading today. Are the 'big guys' liquidating their investments?